Jones v. Miles Laboratories, Inc.

700 F. Supp. 1127, 1988 U.S. Dist. LEXIS 13633, 1988 WL 129512
CourtDistrict Court, N.D. Georgia
DecidedDecember 5, 1988
DocketCiv. 1:86-cv-83-ODE
StatusPublished
Cited by2 cases

This text of 700 F. Supp. 1127 (Jones v. Miles Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Miles Laboratories, Inc., 700 F. Supp. 1127, 1988 U.S. Dist. LEXIS 13633, 1988 WL 129512 (N.D. Ga. 1988).

Opinion

ORDER

ORINDA D. EVANS, District Judge.

This diversity suit for damages is before the court on Defendant’s motion for judgment notwithstanding the verdict. After considering the briefs filed by the parties, Defendant’s motion is granted.

The Plaintiff Randy J. Jones is a hemophiliac who suffers from acquired immune deficiency syndrome (“AIDS”). Elizabeth M. Jones is his wife. In the fall of 1983, Mr. Jones purchased a blood clotting product from the Defendant; he contends the product contained HIV virus which was responsible for his contracting AIDS. He contends Defendant was negligent in manufacturing the product. 1 The jury awarded Mr. Jones $150,000 in medical expenses, $200,000 for pain and suffering, and $750,-000 for lost earnings. The jury awarded *1129 Mrs. Jones $500,000 for her loss of consortium claim.

The pertinent facts, none of which are disputed, are as follows:

The Defendant Cutter Laboratories (“Cutter”) at relevant times was one of four manufacturers of a product called Factor VIII within the United States. Cutter’s Factor VIII product is called Koate; it is a highly concentrated blood clotting product which is manufactured using human plasma as its basic element. The plasma donations of thousands of persons are combined and distilled to produce a lot of Koate. Each lot of Koate is divided and sold in small vials, with there being three to five thousand vials per lot.

The plasma donations allegedly at issue were given by a paid donor named Christopher Whitfield at a plasmapheresis center, Austin Blood Components, Inc. in Austin, Texas. Austin Blood Components then sold Whitfield’s plasma to Cutter, which used it to make Koate.

On October 21, 1983, Christopher Whitfield died of AIDS. Just before he died, he told his treating physician that he was a homosexual. As Mr. Whitfield was the first known AIDS victim in Austin, the local newspaper carried an article about the fact that he had died of AIDS. The Director of Austin Blood Components, Inc. read the article. She checked Austin Blood Components’ records and learned that Whitfield had been a plasma donor both in 1982 and 1983 on many occasions. Other evidence at trial reflected that Whitfield had also donated many times during 1982-1983 at Austin Plasma Center, another plasmapheresis center in Austin.

Austin Blood Components contacted Cutter and revealed what they had learned. Through Austin’s and Cutter’s records, Cutter was able to determine what lots of Koate had contained Mr. Whitfield’s plasma. Cutter sent a letter to all hospitals and doctors who had purchased Koate in the time frame affected by Mr. Whitfield’s donations, recalling all bottles of Koate within the lot numbers which had been made using Mr. Whitfield’s plasma. The letter identified the lots by number, and specifically stated that they contained plasma obtained from an individual who had AIDS.

Clayton General Hospital in Atlanta, Georgia, received Cutter’s recall letter. The hospital identified Plaintiff Randy Jones as a patient who might have received Koate from one of the recalled lots. Specifically Jones’ hospital file reflected that while he had been a patient at Clayton General in September, 1983, the hospital had ordered Koate for him; 2 the Koate which had been ordered consisted of numerous vials within lots 8450, 8460, and 8476. Two of the lots, 8460 and 8476, were subjects of Cutter’s recall letter. Clayton General notified Randy Jones’ physician of this development.

Clayton General Hospital checked and determined that none of the vials of Koate within Lot No. 8460 which had been ordered for Mr. Jones had been used; they were still on the hospital pharmacy shelf. They were returned to Cutter. Most of the vials marked with Lot No. 8476 remained on the pharmacy shelf; they were sent back to Cutter. The hospital records indicate that several vials of Lot No. 8476 were mixed with sterile water and sent to the nursing station for intended infusion into Mr. Jones. However, Jones’ hospital chart identifies only vials from Lot No. 8450 as having been administered to him. One entry on the hospital chart reflects administration of three vials of Koate from an unidentified lot number, but the number of units administered at that time (2010), is more consistent with its being in Lot No. 8450 (670 units per vial, whereas the vials from Lot No. 8476 each contained 290 units). Mr. Jones was billed for Koate from Lot Nos. 8450 and 8476. 3

*1130 In November, 1983, Randy Jones was admitted to Clayton General Hospital again, this time in connection with a severe virus-like illness. Dr. Carlos Osmon, a hematologist, testified that there is now evidence that this type of episode often follows the initial exposure to the HIV virus by four to six weeks, and represents the first assault of the virus on the body’s immune system.

After recovering from the virus-like episode in the fall of 1983, Randy Jones’ general health was good until 1986, when he began experiencing various symptoms known to be associated with a full blown case of AIDS. Mr. Jones, who worked for a contracting firm, was able to continue working until the fall of 1987. Since that time, he has been unemployed and has experienced significant physical discomfort and limitation in his daily activities. The fact that Mr. Jones has AIDS is not disputed.

According to Richard Riojas, Director of Austin Plasma Center, it was routine practice in the plasma industry in Texas in 1982 and 1983 to inquire of a donor whether he was a homosexual and to require him to verify in writing that he was not. Mr. Riojas testified that he could not recall when his center started that procedure, but he believed it was in December of 1982 after FDA recommendations or regulations had come out regarding the necessity to screen out high risk donors, including homosexuals. However, Riojas did not have a copy of the FDA recommendation or regulation at the time of the deposition; he stated he would send it later to Plaintiffs’ counsel. At trial, Plaintiffs did not introduce into evidence or identify any FDA regulation or recommendation to show what Riojas had been referring to.

The evidence was undisputed that in 1982, little was known in the scientific and medical community about AIDS. It was known that the disease particularly victimizes homosexual men, but it was not known how the disease was transmitted. As of the end of 1982, eight hemophiliacs nationwide had been identified as having AIDS. Over the course of 1983, there was a growing fear and suspicion that AIDS might be transmissible through human blood, but there was no proof that this was so. There was no way in 1982 or 1983 to test an individual or to test his blood to see if he was a carrier of AIDS.

The evidence fails to reflect that the Food and Drug Administration or any other governmental agency issued any regulations in 1982 or 1983 requiring plasmapher-esis centers to ask donors if they were homosexuals. 4

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
700 F. Supp. 1127, 1988 U.S. Dist. LEXIS 13633, 1988 WL 129512, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-miles-laboratories-inc-gand-1988.